-
2024-515008-38-00
5
2025-02-14
Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2023-505077-32-00
5
2025-01-28
Locally-advanced or metastatic non-squamous non-small cell lung cancer
-
2024-519041-29-02
6
2025-01-15
Extubation failure and bronchopulmonary dysplasia
-
2023-510109-16-00
4
2025-01-06
Acute Respiratory Distress Syndrome (ARDS) Due to Pneumonia or other I
-
2023-505232-36-00
5
2024-11-15
Essential thrombocythemia
-
2023-508338-33-00
5
2024-10-01
Chronic Inflammatory Demyelinating Polyneuropathy
-
2023-510128-66-00
5
2024-09-02
Participants with treatment-naïve metastatic squamous Non-small Cell L
-
2023-508613-17-00
5
2024-05-29
Neoplasms, Head and Neck
-
2022-502276-23-00
5
2024-04-25
JAK2V617F-positive high-risk Polycythemia Vera
-
2023-504044-34-00
4
2024-04-17
Untreated Chronic Lymphocytic Leukemia
-
2023-504865-21-00
5
2024-04-15
Essential Thrombocythemia patients who have an inadequate response to
-
2023-504923-20-00
5
2024-04-04
Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2022-502193-16-00
5
2023-11-14
Chronic lymphocytic leukemia, Multiple Myeloma and Non-Hodgkin Lymphom
-
2023-507778-42-00
4
2023-03-08
Non-Small Cell Lung Cancer II, III
-
2022-500765-27-00
5
2022-11-03
Hematologic malignancies
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2023-507202-14-00
7
2021-04-29
Upper limb spasticity after stroke or traumatic brain injury
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2023-509338-21-00
4
2025-05-28
Primary immune thrombocytopenia
-
2024-512925-95-00
5
2025-05-16
Advanced/Metastatic Breast Cancer
-
2024-515772-12-00
4
2025-04-18
Lung neoplasm malignant (Stage IV Non-small cell lung cancer)